Adjuvant ArtinM favored the host immunity against Cryptococcus gattii infection in C57BL/6 mice.

IF 2.7 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-06-28 DOI:10.1080/1750743X.2024.2360384

Patrícia Kellen Martins Oliveira-Brito, Gabriela Yamazaki de Campos, Júlia Garcia Guimarães, Michele Procópio Machado, Letícia Costa Serafim, Javier Emílio Lazo Chica, Maria Cristina Roque-Barreira, Thiago Aparecido da Silva

{"title":"Adjuvant ArtinM favored the host immunity against Cryptococcus gattii infection in C57BL/6 mice.","authors":"Patrícia Kellen Martins Oliveira-Brito, Gabriela Yamazaki de Campos, Júlia Garcia Guimarães, Michele Procópio Machado, Letícia Costa Serafim, Javier Emílio Lazo Chica, Maria Cristina Roque-Barreira, Thiago Aparecido da Silva","doi":"10.1080/1750743X.2024.2360384","DOIUrl":null,"url":null,"abstract":"Aim: Cryptococcus gattii causes a severe fungal infection with high mortality rate among immunosuppressed and immunocompetent individuals. Due to limitation of current antifungal treatment, new immunotherapeutic approaches are explored.Methods: This study investigated an immunization strategy utilizing heat-inactivated C. gattii with ArtinM as an adjuvant. C57BL/6 mice were intranasally immunized with heat-killed C. gattii and ArtinM was administrated either before immunization or along with HK-C. gattii. Mice were infected with C. gattii and the efficacy of the immunization protocol was evaluated.Results: Mice that received ArtinM exhibited increased levels of IL-10 and relative expression of IL-23 in the lungs, reduced fungal burden and preserved tissue integrity post-infection.Conclusion: Adjuvant ArtinM improved immunization against C. gattii infection in C57BL/6 mice.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"733-748"},"PeriodicalIF":2.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421300/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2024.2360384","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Cryptococcus gattii causes a severe fungal infection with high mortality rate among immunosuppressed and immunocompetent individuals. Due to limitation of current antifungal treatment, new immunotherapeutic approaches are explored.Methods: This study investigated an immunization strategy utilizing heat-inactivated C. gattii with ArtinM as an adjuvant. C57BL/6 mice were intranasally immunized with heat-killed C. gattii and ArtinM was administrated either before immunization or along with HK-C. gattii. Mice were infected with C. gattii and the efficacy of the immunization protocol was evaluated.Results: Mice that received ArtinM exhibited increased levels of IL-10 and relative expression of IL-23 in the lungs, reduced fungal burden and preserved tissue integrity post-infection.Conclusion: Adjuvant ArtinM improved immunization against C. gattii infection in C57BL/6 mice.

查看原文本刊更多论文

佐剂 ArtinM 有利于 C57BL/6 小鼠宿主对加滕隐球菌感染的免疫力。

目的：加特隐球菌是一种严重的真菌感染，在免疫抑制和免疫功能健全的人群中死亡率很高。由于目前抗真菌治疗的局限性，我们正在探索新的免疫治疗方法。方法：本研究探讨了一种利用热灭活 C. gattii 和 ArtinM 作为佐剂的免疫策略。C57BL/6 小鼠经鼻内免疫热灭活的 C. gattii，在免疫前或与 HK-C. gattii 一起注射 ArtinM。用 C. gattii 感染小鼠并评估免疫方案的有效性。结果接受ArtinM的小鼠肺部IL-10水平和IL-23相对表达量增加，真菌负担减少，感染后组织完整性得到保护。结论佐剂 ArtinM 提高了 C57BL/6 小鼠对 C. gattii 感染的免疫效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.